Palvella Therapeutics, Inc.
NASDAQ:PVLA · NASDAQ Global Market
-$1.46 today
Vol 0.30M · Avg 0.25M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PVLA · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$49.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.17, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 -100.0% | $25.9M -17.6% | $31.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 -100.0% | $2.8M +17.4% | $2.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 -100.0% | $23.1M -20.4% | $29.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | 89.3% -3.2pp | 92.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $22.8M +180.2% | $8.2M -7.3% | $8.8M -82.5% | $50.2M -21.8% | $64.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $15.8M +165.2% | $5.9M +93.2% | $3.1M -81.2% | $16.4M -1.8% | $16.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $38.6M +173.9% | $14.1M +18.8% | $11.9M -82.2% | $66.6M -17.7% | $80.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 | $0 | $0 -100.0% | $2.8M +17.4% | $2.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$35.9M -173.7% | -$13.1M -170.2% | $18.7M +161.3% | -$30.5M +29.7% | -$43.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | -117.7% +20.3pp | -138.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$38.6M -173.9% | -$14.1M -18.8% | -$11.9M +72.7% | -$43.5M +16.1% | -$51.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | -167.8% -2.9pp | -165.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.6M +303.4% | $642.0K -89.8% | $6.3M +768.9% | $721.0K +17925.0% | $4.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.8M +34.8% | $4.3M | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$3.1M +6.8% | -$3.3M -110.9% | $30.6M +199.7% | $10.2M +67.4% | $6.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$41.7M -139.3% | -$17.4M -193.3% | $18.7M +156.2% | -$33.3M +27.2% | -$45.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | -128.5% +17.1pp | -145.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$41.7M -139.3% | -$17.4M -193.3% | $18.7M +156.2% | -$33.3M +27.2% | -$45.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | -128.5% +17.1pp | -145.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 +52.6% | -$8 -153.1% | $15 +149.8% | -$30 +47.8% | -$57 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 +52.6% | -$8 -153.1% | $15 +149.8% | -$30 +47.8% | -$57 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $11.3M +405.4% | $2.2M +75.6% | $1.3M +36.3% | $930.4K +15.3% | $806.8K | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $11.3M +405.4% | $2.2M +75.6% | $1.3M +36.3% | $930.4K +15.3% | $806.8K | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.67B
GH Research PLC
NASDAQ:GHRS
$1.49B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.12B
Savara Inc.
NASDAQ:SVRA
$1.11B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$954.30M
Arbutus Biopharma Corporation
NASDAQ:ABUS
$882.99M
Kura Oncology, Inc.
NASDAQ:KURA
$850.46M
Rezolute, Inc.
NASDAQ:RZLT
$486.76M
ProKidney Corp.
NASDAQ:PROK
$262.25M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PVLA generate?
Palvella Therapeutics, Inc. (PVLA) reported $0.00 of revenue in fiscal 2025.
Is PVLA profitable?
Palvella Therapeutics, Inc. (PVLA) reported -$41,715,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.